Introduction
CD44 is a multifunctional transmembrane glycoprotein involved in cell-extracellular matrix interaction and cellular signaling cascades (1, 2) . The human CD44 gene is located on chromosome 11p13 and consists of 19 exons that encode the full length CD44 (CD44fl) (2) (3) (4) . The first five exons, which contain hyaluronic acid (HA) (5, 6) , collagen (7) , laminin (2) , fibronectin (8) binding site, coding for the extracellular domain. The first 5 and the last 5 exons are constantly transcribed for translation into the standard form (CD44s), whereas the 9-exons located between these regions are subject to alternative splicing, resulting in the generation of CD44 variants (v1 to v10 variants) (9) (10) (11) . Differential splicing of the 10 variable region exons, as well as variable levels in N-glycosylation and Oglycosylation, result in multiple isoforms of CD44 with different molecular weights (12) (13) (14) (15) . These wide varieties of variant isoforms and post-translational modifications are involved in cell-cell and cell-matrix interaction, organ development, neuronal axon guidance, numerous immune functions, lymph node homing, and hematopoiesis (9) .
Many cancer types and their metastases express high levels of CD44 (16) (17) (18) and CD44 is a well-known surface marker of tumor-initiating cells in breast and other tumors (19, 20) . CD44s which is the smallest CD44 isoform, promotes stemness state (21, 22) and is highly expressed in aggressive triple negative breast cancer cells (23) . CD44 + CD24 -/low cells are thought to be responsible for tumor initiation, metastasis, and therapy resistance (24) (25) (26) .
We previously reported that, both CD44s and CD44 full length (CD44fl) are capable of mediating breast tumor cell aggregation, CTC cluster formation, and polyclonal metastases, due to their shared extracellular regions (23) . We found that CD44 directly drives cell aggregation through its intercellular, trans-homophilic interactions, which then recruits and activates its downstream target P21 activated kinase 2 (PAK2) (23) . Notably, this trans-homophilic CD44 interaction is HA independent in directing tumor cell aggregation. Since CTC clusters possess 23-to 50-fold increased metastatic potential and predict worse prognosis compare to single CTCs (27) (28) (29) , the biochemical features and the importance of CD44 homophilic interactions in PAK2 activation need to be further investigated.
In this study, to further elucidate the biochemical mechanisms underlying CD44 homophilic interactions, we utilized computational analyses and machine learning-assisted modeling to guide the mutagenesis studies. Based on the relative short sequence of CD44s (encoded by the transcript X4 isoform), we modeled its structure, identified the three extracellular Domains I-III, and further predicted the "hot spot" amino acids in CD44 Domain I and II that are essential for CD44 homophilic dimerization in trans. Mutations of these sites abolished CD44 homophilic interactions, and reduced cell aggregation in vitro and/or lung colonization in vivo. Importantly, these mutations also interfered CD44 downstream signaling and decreased PAK2 activation.
Results

Standard CD44 (CD44s) and full length CD44 (CD44fl) forms both trans-and cisdimers.
Protein homophilic interactions can take place intercellularly (trans) between neighboring cells or intracellularly (cis) within the same cell. We recently identified that CD44 (CD44s and CD44fl) can form trans-homophilic interactions to mediate CTC cluster formation and drive polyclonal metastases (23) . To further determine whether CD44 directs both trans-and cishomophilic interactions, we designed and conducted two experiments using CD44s positive MDA-MB-231 breast cancer cells and CD44 negative HEK-293 cells.
First, we observed that upon SDS-PAGE analysis, the endogenous CD44s of 361 amino acids (aa) from the MDA-MB-231 single cell lysate showed at least three monomer forms, of small-size (50 kDa*, medium-size (60 kDa # ), and big-size (80 kDa^) ( Fig.1A) , possibly due to different levels of glycosylation (12) (13) (14) (15) . To conform glycosylation of CD44s, we made the CD44s mutant 6Ns/Q (with six N residues converted to Q) with lost N-glycosylation sites. When overexpressed in HEK-293 cells, CD44s mutant 6Ns/Q (CD44s M) showed a molecular weight of ~50 kDa* ( Fig. 1B, left  panel) . In addition, when using the PNGase F (PN) to partially remove N-glycans in MDA-MB-231 cells, CD44s displayed lower molecular weights to ~60 kDa # (Fig. 1B,  right panel) . These data suggest that CD44s displays different molecular weights dependent on glycosylated levels.
When
the cross-linking reagent disuccinimidyl suberate (DSS) was utilized to stabilize protein complexes, minimal CD44s cis-dimers were detected in the MDA-MB-231 single cell lysates with or without DSS treatment ( Fig. 1A) . After these single cells aggregated overnight as clusters on the Poly-Hema coated plate, at least three forms of trans-dimers from three molecular sizes (50kDa, 60kDa, and 80kDa) were increasingly presented at molecular weights of approximately 100 kDa (**), 120 kDa ( ## ), and 160 kDa (^^), respectively upon DSS treatment ( Fig. 1A) , suggesting that CD44s favorably form trans-dimers. Furthermore, the CD44s molecules of small-size and by guest on February 2, 2020 http://www.jbc.org/ Downloaded from medium-size made the majority of the trans-CD44s dimers whereas the big-size CD44s had little dimerization ( Fig. 1A) .
In the CD44-negative HEK-293 cells transfected with a plasmid encoding the CD44fl of 761aa, there was one main monomer band at ~110 kDa ( @ ) (Fig. 1C) , along with the detectable cis-dimers in the single cell lysates as well as trans-dimers (220 kDa [ @@ ]) in the clustered cell lysates after DSS cross-linking (Fig. 1C) . These data suggest that CD44s and CD44fl might have distinct preferences for cis-and trans-dimers in different cells.
Second, using co-immunoprecipitation (Co-IP) we detected CD44 homophilic interactions within HEK-293 cells transfected with tagged CD44s-Flag and CD44fl-HA. For the trans-dimer analyses, the Flag-and HA-tagged CD44 plasmids were separately transfected into two different sets of cells, and then these two sets of cells in suspension were mixed and aggregated into clusters prior to cell lysis ( Fig. 1D) . For cis-dimer analyses, the Flag-and HA-tagged CD44 plasmids were co-transfected into the same set of cells and then single cells in suspension were harvested for Co-IP ( Fig.  1E) . Consistent with Fig. 1D , the interactions between CD44-Flag and CD44-HA were detected via Co-IP with the anti-Flag antibody from both experiment designs ( Fig.  1D and 1E ), suggesting that CD44 has an ability to form both intracellular and intercellular homophilic interactions. As our research is mainly interested in CD44mediated cell aggregation, the following experiments set out to elucidate the biochemical features underlying CD44 intercellular trans-dimerization.
Machine learning-based prediction of the CD44 binding sites for homophilic interactions
CD44 is encoded by 19 exons in human cells and 20 exons in mouse cells with the extra exon 5a ( Fig. 2A) . As indicated, the first 5 exons of human CD44 encode the N-terminal 223 aa within the extracellular region, which is shared across all the isoforms, and the inserted exons 6-14 generate multiple CD44 variants through alternative splicing ( Fig.  2A) . CD44s is the smallest CD44 isoform, lacking the entire variable region made by the exons 6-14 ( Fig. 2A) . Based on the fact that CD44s preferentially mediates trans-dimers in MDA-MB-231 breast cancer cell clusters and the relative better reliability using the shorter sequence for modeling, we focused on modeling CD44s monomers using the webserver iTasser (30) and CD44s dimers using Bayesian active learning (BAL), a machining learning-assisted protein docking method (32) .
We identified a four-Domain structure of the CD44s monomer with three extracellular Domains I-III and the Domain IV containing the transmembrane and cytoplasmic regions ( Fig. 2A) . Among the top homodimer models of CD44s, most of representative dimer structures indicate the homophilic interactions between the Domains I-II from both monomers. The first-ranked homodimer model suggests head-to-head dimerization from opposite directions at a near 180° angle ( Fig. 2B) . Interestingly, Domain II of monomer 1 was suggested to dock between Domains I and II of monomer 2. From multistage protein docking, collective analyses of all top dimer models predicted that the hot spot residues visualized in warmer colors are essential for CD44 dimerization, including 12 amino acids (S45, E48, F74, C77, R78, Y79, I88, R90, H92, P93, N94, and C97) within the Domain I and 5 amino acids (I106, Y155, V156, Q157, and K158) within the Domain II ( Fig. 2C) .
Mutant CD44 disrupts trans-dimerization and homophilic interactions
In order to further determine the importance of these hot spot residues in CD44 homophilic interactions and tumor cell aggregation, we mutated most of these amino acids (except for H92 and P93) into alanine for functional studies. H92 and P93 were kept intact to avoid disruption of CD44 protein stability. As listed in Fig. 2C , the rest of 10 hot spot residues (marked in red) of Domain I were mutated to generate the CD44 DI mutant, and the 5 residues (marked in blue) of Domain II were mutated to make the CD44 DII mutant. The CD44 mutant ΔN21-97 with truncated Domain I (residues 21-97) served as a positive control to disrupt the CD44 trans-homophilic interactions (23) . All the three mutants were Flag-tagged at the Cterminal (same as the wild-type CD44s-Flag).
We then investigated whether these predicted sites have impact on CD44 transdimerization by transfecting the mutated and wild-type CD44s (Flag-tagged) into HEK-293 cells. When the cells were aggregated into clusters, half of the cells were treated with the cross-linker DSS for dimer detection. While the wild-type CD44s-Flag dimerized mainly by the medium-size CD44s, the three mutants of CD44s (ΔN, DI, and DII) dramatically disrupted its self-dimerization ( Fig. 3A) . Furthermore, we utilized a second method of Co-IP to evaluate the transhomophilic interactions between CD44-Flag and CD44-HA. CD44-Flag (wild-type or mutant) and CD44fl-HA were separately transfected into two different sets of HEK-293 cells, and then these two sets of cells were mixed for cell aggregation on Poly-Hema coated plate. After three-hour clustering, cells were harvested and lysed for Co-IP with the anti-HA and the anti-Flag antibodies. The trans-homophilic interactions between the wild-type CD44-Flag and CD44fl-HA proteins were reciprocally detected, respectively ( Fig. 3B) . However, the Flag-tagged ∆N21-97, DI, and DII mutants were mostly undetectable in the anti-CD44-HA pull-down complex; and vice versa, CD44-HA was not detected from the anti-Flag pull down with the CD44 mutants ( Fig. 3B) . These results demonstrate that the CD44 trans-dimerization and homophilic interactions are vitally dependent on the predicted amino acids in Domains I and II. To further identify potential interaction pairs between these amino acids, we conducted machine learning-based CD44 structural modeling and predicted across-chain residue interactions for each hot spot amino acid ( Table 1) .
Many of those predicted interactions are based on opposite charges, aromatic, polar-polar, charge-polar, and hydrophobic-hydrophobic partnerships.
CD44 mutants block PAK2 activation
To investigate whether these CD44s mutants have impact on the CD44 downstream signaling, such as the activation of PAK2, we co-transfected PAK2-HA and Flag-tagged CD44s WT, ∆N21-97, DI, or DII mutants into HEK-293 cells. After 48 hours, cells were transferred to Poly-Hema coated plates to form clusters. In comparison to the CD44s WT, all three CD44 mutants, ∆N21-97, DI and DII blocked the Ser20-phosphorylation (activation) of PAK2 ( Fig. 4A) . As PAK2 is a cytoplasmic kinase and its interaction with CD44 is predicted to depend on the CD44 cytoplasmic tail, the CD44 extracellular mutants remained interaction with PAK2 determined by Co-IP ( Fig. 4B) . We further confirmed that knockdown of CD44s in MDA-MB-231 cells decreased PAK2 activation ( Fig. 4C) . These data suggest that CD44 trans-homophilic interactions are required for PAK2 activation.
CD44 mutants interfere cell aggregation in vitro and lung colonization in vivo
Since the CD44 extracellular mutants abolished CD44 trans-homophilic interactions and its downstream PAK2 activation, we next evaluated their impact on cell-cell aggregation in vitro and lung colonization in experimental metastasis. During the clustering assays on Poly-Hema coated plates, cells transfected with ∆N, DI and DII dramatically decreased the number of larger cell clusters (6-10 cells and >10 cells), compared to the CD44s-transfected HEK-293 cells ( Fig. 5A and B ), suggesting CD44 trans-homophilic interactions drive cell-cell aggregation in vitro.
To determine if these mutants have impact on the CTC cluster formation during lung colonization in vivo, we infused the vehicle, wildtype (WT) CD44s or mutant CD44stransfected MDA-MB-231 CD44 KO cells into the immunodeficient NSG mice via tail vein. We imaged the lung seeding efficiencies of these cells at 24 hours post tail vein infusion.
Transfection-based WT CD44s expression rescued the lung colonization of CD44s KO cells which was not rescued by the DII mutant ( Fig. 6A) . Consistently, 48 hours after infusion, the KO cells transfected with DII mutant showed significantly fewer big clusters with more than four breast tumor cells (>=4 cells) in comparison to WT CD44s (Fig. 6B) . These data suggest that Domain II mutant interferes lung colonization of tumor cells.
Taken together, our studies have demonstrated that endogenous CD44s prefers trans-homophilic dimerization in breast tumor cells. In addition, combined structural modeling and site-directed mutagenesis revealed that CD44 trans-dimerization and subsequent cell aggregation are dependent on certain residues located within Domains I and II, which also impact PAK2 activation. Furthermore, Domain II mutant significantly decreases lung colonization.
Discussion
Homology modeling, protein docking, and machine learning have shown the great power in the structural modeling of CD44 dimerization in our studies; and they will continue to expedite the CD44-PAK2 structural studies and subsequent drug development. Indeed, machine learning and deep learning have been applied to exponentially transforming the future technology and increasing the knowledge base, not only in biological research, but also in medicine and other fields.
CD44 is one of the most studied transmembrane glycoproteins in cancer, and plays a key role in cell adhesion, signal transduction and cytoskeleton remodeling (5) . It is also a well-known breast tumor-initiating cell marker, and associated with chemoresistance and metastasis (24) (25) (26) . Most significantly, CD44 has been recently unveiled to directly couple stem cell properties and metastasis through its homophilic interaction-driven CTC cluster formation and polyclonal metastasis (23) . CD44 homophilic interactions in tumor clusters also activate PAK2 signaling pathway that contributes to enhanced stemness and metastatic potential of CTC clusters (23) . This finding suggests that targeting CD44-CD44 interactions could potentially interrupt CTC clustering and consequently reduce metastasis. The new identification of the amino acids in Domains I and II essential for CD44 trans-dimerization will facilitate the development of therapeutics that disrupt CTC clustering and therefore block metastasis. Our future studies will further determine the specific contribution of each amino acid in both Domains to CD44 homophilic interactions. 7 strategy for all tumor cells with different CD44 variants. Nevertheless, it is also necessary to distinguish tumor cell clustering from CD44-mediated normal cell functions, such as those in lymphocytes. It is worth noting that CD44 shows different bands of molecular weights and its medium-size form dominates the trans-dimerization in tumor cell clusters. This might provide a unique opportunity to identify targetable posttranslation modification features, such as glycosylation patterns of CD44 in tumor clusters for specific drug development and therapeutics.
PAK2 harbors three sites of phosphorylation, and the Ser20 is known to be phosphorylated by Akt or Protein kinase B (PKB) (36) . Phosphorylation of PAK2 at Ser20 protects cells from apoptosis, promotes cell survival, and cellular migration (37, 38) . As the mutations of amino acids in CD44 extracellular Domains or deletion of CD44 Domain I did not interrupt CD44-PAK2 interaction, it warrants further identification of the sites mediating CD44 and PAK2 interaction, which most likely locates in transmembrane or cytoplasmic Domain IV. Identification of CD44 regions and amino acids for PAK2 binding could also facilitate the development of peptides to target these sites, interfere activation of PAK2, and thereby inhibiting metastasis.
CTCs are cells that have detached from primary tumor and entered the bloodstream. Although extraordinarily rare, they are considered the seeds for the subsequent growth of metastasis in distant organs, especially CTC clusters. In addition to CD44-mediated CTC cluster aggregation, there might exist CD44-independent mechanisms underlying CTC cluster formation to be targeted for drug development (23) (24) (25) . By screening FDAapproved compounds, Na+/K+ ATPase inhibitors were identified as potential drugs to suppress metastasis by targeting CTC clusters (29) . In vivo administration data of these inhibitors suggest that CTC cluster prevention should be implemented at the time of localized disease and before tumor dissemination into distant sites. Meanwhile, if similar mechanisms support the survival and aggregation of CTC clusters before extravasation, targeting CTC clusters could also result in therapeutic benefits for patients with late stage disease. However, given the time from cancer cells entering into circulation to reaching a secondary organ is a relative short-time window, it is equally important to directly target clustered CTCs and micro-metastases in distant organs in addition to prevent tumor cell aggregation prior to intravasation as well as CTC cluster formation in circulation. A better understanding of the upstream and downstream signaling pathways underlying CTC cluster formation could help control and block cancer metastasis.
Methods
Animal studies. All animal procedures and experimental procedures have been performed under approval by Northwestern University Animal Care and Use Committee (ACUC) and complied with the NIH Guidelines for the Care and Use of Laboratory Animals. All mice used in this study were kept in specific pathogen-free facilities in the Animal Resources Center at Northwestern University. 8-10 weeks old female NSG mice were used for tail vein injection of human cells. The patient-derived xenograft (PDX) tumors were established as described previously (18, 24) .
Tail vein injection and lung dissection. For tail vein injection, L2G labeled 231-CD44KO cells overexpressing CD44s-Flag, CD44s-Domain I mutant-Flag (DI), and
CD44s-Domain II mutant-Flag (DII) in 200 µl of PBS were injected into NSG mice via tail vein using the 28G syringe needles (BD, 329461). 48 hours post tail vein injection, the mice were euthanized for tissue dissection. After washing with cold PBS, the dissected lungs were imaged under fluorescence microscopy.
Bioluminescence imaging. After intraperitoneal injections with 100 μl of Dluciferin (30mg/ml, Gold Biotechnology, 11 5144-35-9), mice were anesthetized with isoflurane. Bioluminescence images were acquired on day 0, 1, and 2 using the Spectral Instrument Imaging Spectral Lagos (SII LAGO) and the signals were presented as total flux (photons/second, p/s) and fold changes of the total flux signals (Aura, version 2.2.1.1). Acquisition times ranged from 5 second to 5 minutes.
Cell lines. Human breast cancer cell line
MDA-MB-231 and an immortalized HEK-293 cell were purchased commercially from ATCC. L2G labeled 231-CD44KO cells were established as described previously (23) . Early passage of cells (<20 passages) were maintained in DMEM (Fisher Scientific, SH30243FS) supplemented with 10% FBS (Takara Bio, 631106) and 1% penicillinstreptomycin (P/S) (Sigma-Aldrich, P4333-100ML).
Transfections. CD44s-∆Nd21_97-Flag, CD 44s-Domain I mutant-Flag (DI), CD44s-Domain II mutant-Flag (DII), and CD44s-6Ns/Q mutant for de-N-glycosylation (6 Ns, including N25, N57, N100, N101, N110, and N120, converted to Q) were made by mutagenesis (GeneScript) based on pCMV6-Flag-CD44. For plasmid-cDNA overexpression experiments, pCMV3-C-GFP Spark Control Vector (Sino Biological, CV026), pCMV3-HA-PAK2 (Sino Biological, HG10085-NY), pCMV3-CD44-HA (Sino Biological, HG12211-CY), pCMV6-Flag-CD44 (OriGene, RC221820), CD44s-∆Nd21-97-Flag, CD44s-Domain I mutant-Flag (DI), and CD44s-Domain II mutant-Flag (DII) were transfected into HEK-293 cells using PolyJet (SigmaGen Laboratories, SL100688). At 48 hours post transfection, cells were trypsinized and filtered through 35 µm nylon mesh to make single cell suspension and lysates. For cluster formation, single cells aggregate upon incubation on the Poly-HEMA (Sigma-Aldrich, P3932-10G) coated dish for 3-6 hours. Collected single and clustered cells were used for cross-linking assay, coimmunoprecipitation, and western blotting. L2G labeled MDA-MB231 cells -CD44KO cells were double transfected with plasmid-cDNA overexpression using JetPRIME (VWR, 89129-920). For siRNA transfection, 100nM siRNAs against CD44 (Dharmacon, L-009999-00-0010), PAK2 (Dharmacon, L-003597-00-0020), and negative control (Dharmacon, D-001810-10-50) were transfected using Dharmafect (Dharmacon, T-2001-03) according to the manufacturer's protocol. On the following day, medium was changed and cells were re-transfected for the second time prior to be collected for analyses.
PNGase F treatment.
For removing Nlinked oligosaccharides from CD44s, used PNGase F according to manufacturer's protocol (New England Biolabs, P0704S). Briefly, MDA-MB-231 cell lysates were first denatured with provided denature buffer for 10 min and incubated with 1000U of PNGase F to cleave N-glycans.
Co-immunoprecipitation (Co-IP) and
Western blotting (WB). After washing twice in cold PBS, cells were lysed in RIPA buffer (cell signaling, 9806S) or IP lysis buffer (Thermo Fisher Scientific, 87787) with protease inhibitor cocktail (Thermo Fisher Scientific, 78440) and incubated for 30 minutes on ice. Protein concentration was determined by Protein Assay Dye Reagent (Bio-RAD, 500-0006). For Co-IP, equal amounts of protein of each sample were incubated with anti HA Magnetic Beads (Thermo Fisher Scientific, 88836) or anti-FLAG M2 Magnetic Beads (Sigma-Aldrich, M8823-5ML) overnight at 4°C. For elution, 0.1M glycine (pH 2-3) was added and incubated for 5-10 minutes at room temperature prior to the supernatant collection. Then the same amount of Tris-Buffered Saline (TBS) was added for neutralizing the low pH. For WB, equal amounts of protein were diluted in 10% βmercaptoethanol contained SDS-PAGE loading buffer (Bio-RAD 4Laemmli Sample Buffer Cat. #161-0747). Proteins were resolved by size using 4-20% or 7.5% SDS-PAGE gel, and then transferred to 0.2 μm pore size of Nitrocellulose membranes. Blocking with 5% BSA in TBS/0.1% Tween 20 for 1 hour at room temperature and incubated with primary antibodies for 1 hour at room temperature or 4 °C overnight. The following primary antibodies and dilutions were used: CD44 (1:1000, Thermo Fisher Scientific, MA513890), FLAG (1:1000, Sigma-Aldrich, F1804-200UG), HA (1:500, Santa Cruz, 12CA5), PAK2 (1:1000, ThermoFisher, PA5-20254), phospho-PAK2 (1:1000, Cell Signaling Technology, 2607T), β-actin (1:5000, abcam, ab8224). After washing primary antibodies in TBS/0.1% Tween 20, membrane was incubated with Horseradish peroxidase (HRP)-conjugated secondary antibodies (mouse: 1:10000, Promega, 402B, rabbit: 1:10000, Promega, W401B) for 1 hour at room temperature. HRP-conjugated secondary antibodies were detected by enhanced chemiluminescence (ECL) (Thermo Fisher Scientific, 32132). Cross-Linking Assay. After two washings in cold PBS, collected cells were treated with 2.5mM of Crosslinking reagent disuccinimidyl suberate (DSS) (Thermo Fisher, 21655) for 2 hours on ice. Then the quench solution (1M Tris-HCl pH7.5, 1:100 dilution) was added to a final concentration of 10 mM for 15 minutes on ice. Finally, the cells were lysed with RIPA buffer for WB or IP lysis buffer for Co-IP.
Cell clustering assay. After 48 hours post transfection, cells were trypsinized and filtered through 35 µm nylon mesh to make single cell suspension. Cells were suspended and incubated onto Poly-HEMA coated 24well plates. Cells were observed under microscope for 4 hours at room temperature with images taken at various time points.
Structural Modeling. The 3D structure of CD44 antigen derived from the transcript isoform 4 precursor (NM_001001391) was first built using the webserver iTasser (30) . It was then rigidly docked to itself using the webserver ClusPro (31) under the homodimer mode. The top-10 initial models under the default ClusPro scoring function were refined using Bayesian active learning (BAL) (32) . BAL describes protein flexibility and motions in complex normal modes from cNMA (33, 34) , adopts a scoring function derived from machine learning, samples conformations using a novel Bayesian active learning method, and estimates the conditional probability, the uncertainty, and the quality range of each model. The refined models were re-ranked based on their estimated conditional probabilities of being near-native (interface root mean squared deviation not exceeding 4Å). Furthermore, each residue was assigned a probability of being at the dimer interface by weighting models by their conditional probabilities and averaging the binary indicators for putative interfaces across all models. The maximum value of the residue probability is 1, indicating that the corresponding residue is surely at the interface given that all structural models contain at least one near-native dimer structure. Similarly, each across-chain residue-pair was assigned a probability of being in contact (if any pair of heavy atoms are within 5Å). The protein structures and dimerization "hot spots" were visualized using the computer program PyMol (35) .
Statistical analysis.
For image analysis, images were taken at least 5 random fields of the clustering cells and the fluorescence lungs images from 3 mice. A two-tailed Student's t-test was used to evaluate the pvalues, and p <0.05 was considered statistically significant and represented with one star (*). Probabilities under 0.01 were represented with two stars (**) and under 0.001 represented with three stars (***). Data are presented as mean ± standard deviation (SD). 
Figure legends
Figure 2. Prediction of CD44s extracellular binding sites for homophilic interactions
